Nivolumab in chemotherapy-resistant cervical cancer: report of a vulvitis as a novel immune-related adverse event and molecular analysis of a persistent complete response

BACKGROUND: Treatment options for advanced cervical cancer are limited and patients experiencing recurrence after first-line cisplatin-based chemotherapy and bevacizumab have a poor prognosis. A recent phase II study in advanced cervical cancer has demonstrated a disease control rate of 68.4% with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Baettig, Florence, Vlajnic, Tatjana, Vetter, Marcus, Glatz, Katharina, Hench, Jürgen, Frank, Stephan, Bihl, Michel, Lopez, Roberto, Dobbie, Michael, Heinzelmann-Schwarz, Viola, Montavon, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824124/
https://www.ncbi.nlm.nih.gov/pubmed/31672171
http://dx.doi.org/10.1186/s40425-019-0742-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824124/
https://www.ncbi.nlm.nih.gov/pubmed/31672171
http://dx.doi.org/10.1186/s40425-019-0742-6

Ejemplares similares